Biotech RadarJobs updated

COMPANY

Kailera Therapeutics

HQ: Waltham, MA source · kailera.com ↗

Clinical Phase 3

23 open jobs · last seen Oct 23, 2026 · 11 sources

Keywords: metabolic obesity small molecule Overweight Obesity With Diabetes Overweight With Diabetes End Stage Renal Disease Renal Impairment Ribupatide KAI-7535 KAI-9531

Location: Waltham, MA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Since the raise (Apr 16, 2026): 23 of 23 open jobs were first seen after it.

23Open jobs$1.2BRaised (2 yrs)8Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Manager, Patient RetentionWaltham, MassachusettsOct 21, 2026Oct 22, 2026
Director, Analytical Development and Quality ControlUS-RemoteOct 20, 2026Oct 21, 2026
Associate Director, CMC OperationsUS-RemoteOct 19, 2026Oct 20, 2026
Vice President, CMC Regulatory AffairsUS-RemoteOct 19, 2026Oct 20, 2026
Vice President, Global Supply ChainUS-RemoteOct 16, 2026Oct 17, 2026

See all 23 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (23 open jobs at last check). source ↗
  2. Trial start Phase 1: A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide source ↗
  3. Raise IPO: $625M (total, as published), announced Apr 16, 2026. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 2: Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity source ↗
  5. Trial start Phase 2: Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes source ↗
  6. Trial start Phase 3: Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes source ↗
  7. Trial start Phase 3: Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes source ↗
  8. Trial start Phase 3: Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes source ↗
  9. Trial start Phase 1: A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or Overweight source ↗
  10. Raise Private equity round — Series B: $600M (total, as published), announced Oct 14, 2025. Source: company release on GlobeNewswire. source ↗
  11. Trial start Phase 1: A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 23

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Manager, Patient RetentionWaltham, MassachusettsOct 21, 2026Oct 22, 2026Not stated
Director, Analytical Development and Quality ControlUS-RemoteOct 20, 2026Oct 21, 2026Not stated
Associate Director, CMC OperationsUS-RemoteOct 19, 2026Oct 20, 2026Not stated
Vice President, CMC Regulatory AffairsUS-RemoteOct 19, 2026Oct 20, 2026Not stated
Vice President, Global Supply ChainUS-RemoteOct 16, 2026Oct 17, 2026Not stated
Vice President, CMC Development and Drug Delivery InnovationUS-RemoteOct 16, 2026Oct 17, 2026Not stated
Associate Director, Global Regulatory Labeling and Ad PromoUS-RemoteSep 18, 2026Oct 9, 2026Senior
Associate Director, Global Regulatory AffairsUS-RemoteSep 18, 2026Oct 9, 2026Senior
Senior Scientist, Analytical Development and Quality ControlWaltham, MassachusettsSep 16, 2026Oct 9, 2026Senior
Director, Clinical Data ManagementUS-RemoteSep 14, 2026Oct 9, 2026Senior
Senior Medical Director, Clinical DevelopmentWaltham, MassachusettsSep 11, 2026Oct 9, 2026Senior
Director, Financial Planning & Analysis (FP&A) - Technical OperationsWaltham, MassachusettsSep 10, 2026Oct 9, 2026Senior
Senior Director, Clinical Data ManagementUS-RemoteSep 4, 2026Oct 9, 2026Senior
Medical Director, Clinical DevelopmentUS-RemoteAug 28, 2026Oct 9, 2026Senior
Associate Director, Device EngineeringUS-RemoteAug 19, 2026Oct 9, 2026Senior
Associate Director, Analytical Development and Quality ControlUS-RemoteJul 22, 2026Oct 9, 2026Senior
Vice President, Program ManagementWaltham, MassachusettsJul 16, 2026Oct 9, 2026Executive
Director, Program ManagementWaltham, MassachusettsJul 1, 2026Oct 9, 2026Senior
Medical Science Liaison, Field Medical Affairs (Regional Medical Liaison) (Greater Texas)US-RemoteJun 29, 2026Oct 9, 2026Mid
Senior Vice President, Clinical DevelopmentWaltham, MassachusettsJun 22, 2026Oct 9, 2026Executive
Associate Director, Statistical ProgrammingUS-RemoteMay 26, 2026Oct 9, 2026Senior
Associate Director/Director, Program Management (Regulatory Submissions)US-RemoteMay 26, 2026Oct 9, 2026Senior
Associate Director, Bioanalytical SciencesWaltham, MassachusettsMay 26, 2026Oct 9, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Funding

Raised: $1.2B. Last 2 years.

Clinical trials (lead sponsor) 8

RecordTitlePhaseStatusStartPrimary completion
NCT07284979Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have DiabetesPhase 3Active, not recruitingDec 30, 20252028-03 (estimated)
NCT07284901Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesPhase 3Active, not recruitingJan 12, 2026Mar 27, 2028 (estimated)
NCT07284875Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have DiabetesPhase 3Active, not recruitingDec 18, 20252028-02 (estimated)
NCT07793929A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of RibupatidePhase 1RecruitingSep 8, 2026Feb 8, 2028 (estimated)
NCT07497880Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related ComorbidityPhase 2Active, not recruitingApr 6, 2026Jul 7, 2027 (estimated)
NCT07458269Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have DiabetesPhase 2Active, not recruitingMar 4, 20262027-05 (estimated)
NCT07294898A Study to Investigate the Effect of a Low-fat Meal and Evening Dosing on KAI-7535 in Participants Living With Obesity or OverweightPhase 1CompletedDec 15, 2025Jan 26, 2026 (actual)
NCT07044401A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass IndicesPhase 1CompletedJul 14, 2025Nov 13, 2025 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Connect

See your connections at Kailera Therapeutics on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback